PE/Cyanine7 anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CTL clone V4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
2. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
3. Perruzza L, et al. 2019. Sci Rep. 9:9315. PubMed
4. Wang X, et al. 2019. Cell Res. 29:787. PubMed
5. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
6. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
7. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
8. Proietti M, et al. 2019. Nat Commun. 10:250. PubMed
9. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
10. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
11. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
12. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
13. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
14. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
15. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
16. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
17. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
18. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
19. Crespo ÂC, et al. 2020. Cell. 182(5):1125-1139. PubMed
20. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
21. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
22. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
23. Diao L, et al. 2022. iScience. 25:105511. PubMed
24. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
25. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
26. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
27. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
28. Kaufmann U et al. 2019. Cell metabolism. 29(5):1104-1118 . PubMed
29. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
30. Rolla S, et al. 2010. J Immunol. 184:6124. PubMed
31. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
32. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
33. Wang C, et al. 2021. Cell Stem Cell. . PubMed
34. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
35. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
36. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
37. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
38. Ma YV, et al. 2021. MAbs. 13:2003281. PubMed
39. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
40. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
41. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
42. Wang H, et al. 2019. Nat Commun. 10:1898. PubMed
43. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
44. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
45. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
46. An J, et al. 2022. iScience. 25:103570. PubMed
47. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
48. Ohmichi Y, et al. 2011. J Exp Med . 208:1015. PubMed
49. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
50. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
51. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
52. Wang W, et al. 2020. Immunity. 51(6):1102-1118.e7.. PubMed
53. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
54. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
55. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
56. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
57. Lee P, et al. 2014. J Immunol. 192:178. PubMed
58. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
59. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
60. Yang J, et al. 2022. Microbiome. 10:149. PubMed
61. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
62. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
63. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
64. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
65. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
66. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
67. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
68. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
69. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
70. Zhou G, et al. 2019. FASEB J. 33:11396. PubMed
71. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
72. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
73. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
74. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
75. XS R, et al. 2015. Diabetes. 64 90. PubMed
76. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
77. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
78. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
79. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
80. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
81. Busse DC, et al. 2020. J Virol. 94:00:00. PubMed
82. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
83. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
84. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
85. Kitajima Y, et al. 2022. Cells. 11:. PubMed
86. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
87. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
88. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
89. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
90. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
91. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
92. Wang W, et al. 2021. STAR Protocols. 2(3):100756. PubMed
93. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
94. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
95. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
96. Li C, et al. 2018. Cell. 174:285. PubMed
97. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
98. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
99. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
100. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
101. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
102. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
103. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
104. Godwin MS, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 320:L393. PubMed
105. Prüss H, et al. 2017. Nat Neurosci. 10.1038/nn.4643. PubMed
106. Kimura S, et al. 2020. Am J Transplant. 20:977. PubMed
107. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
108. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
109. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
110. Ambrosino E, et al. 2006. Cancer Res . 66:7734. PubMed
111. Nagamata S, et al. 2019. Sci Rep. 9:3911. PubMed
112. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
113. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
114. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
115. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
116. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
117. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
118. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
119. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
120. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
121. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
122. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
123. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
124. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
125. Groves HT, et al. 2020. MBio. 11:e03236-19. PubMed
126. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
127. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
128. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed

RRID

AB_312706 (BioLegend Cat. No. 100421)
AB_312707 (BioLegend Cat. No. 100422)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis